Post trial access (PTA) refers to the provision of continued access to a treatment or medication for patients who have participated in a clinical trial, after the trial has concluded. In the context of cancer, PTA is particularly significant as it can provide ongoing benefits from innovative therapies that are not yet commercially available.
